slt

Amy Pan

Chief Financial Officer

Experience and Expertise

Amy is the Global Financial Controller at Sirtex and a member of the Senior Leadership Team. Her expertise is resolving complex US-China business matters with a focus on diagnosing, unearthing and repairing otherwise undetected deficiencies in global financial reporting, accounting, compliance, and internal controls. Amy is an expert at providing sharp, scalable processes and procedures in compliance with global regulatory requirements and focuses on facilitating international growth and partnerships.

After 4 years at KPMG, she held a variety of senior financial roles focused on leading global finance, compliance and audit projects at Teradyne (US), Dextrys (China), and as CFO of Ryerson China Limited in Shanghai, where she served as a key business advisor to the CEO. Prior to Sirtex she was Vice President of Finance at Ancra Group, where she assisted the CFO in managing the finance functions of 18 companies and led the integration of financial reporting and processes resulting from major global acquisitions.

She is bilingual in English and Mandarin, bicultural in American and Asian norms, and thrives in helping companies successfully navigate business and financial complexities as they pursue their global initiatives.

Amy holds a Master of Science in Accounting from Bentley College, a Master of Business Administration from University of Illinois, and a Bachelor of Arts in Economics from the Shanghai University of Finance and Economics.




slt
Kevin R. Smith
CEO

slt
Paul Andreassi
Executive Vice President of Global Quality Assurance

slt
Jesse Hansen
Global Head of Marketing

slt
Francis Jannot
Executive Vice President of International Sales

slt
Cathleen Lowndes
Chief Human Resources Officer

slt
Amy Pan
Chief Financial Officer

slt
Suki Shergill
Executive Vice President, Global Pricing & Market Access

slt
Kevin P. Smith
General Counsel & Executive Vice President, Business Development

slt
Grant Spindler
Global Head of Operations

slt
MaryLou Stroumbos
Executive Vice President, Regulatory Affairs

slt
Mark Turco
Global Chief Medical Officer & Executive Vice President of Research & Development



Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

Now leaving sirtex.com

You are about to leave the Sirtex Website. This link is provided to you as a service and will take you to the Sirtex Virtual Booth.

Sirtex is responsible for the content of the Virtual Booth, which is hosted on a website maintained by a third-party. Except for Sirtex’s Virtual Booth experience, please be aware that Sirtex takes no responsibility for the other content of these external sites, nor do we endorse, warrant, or guarantee the products, services or information described or offered on other internet sites.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×

Effective May 7, 2021, SIR-Spheres will have the following indication for use:
SIR-Spheres Y-90 resin microspheres are indicated for the treatment of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy.

Click here to view our Technical Bulletin.

Ok